Cargando…

Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes

OBJECTIVE: This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux‐en‐Y gastric bypass (RYGB) with healthy controls. METHODS: A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m(2) were c...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsogiannos, Petros, Kamble, Prasad G., Pereira, Maria J., Sundbom, Magnus, Carlsson, Per‐Ola, Eriksson, Jan W., Espes, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986425/
https://www.ncbi.nlm.nih.gov/pubmed/33624436
http://dx.doi.org/10.1002/oby.23093
_version_ 1783668442494140416
author Katsogiannos, Petros
Kamble, Prasad G.
Pereira, Maria J.
Sundbom, Magnus
Carlsson, Per‐Ola
Eriksson, Jan W.
Espes, Daniel
author_facet Katsogiannos, Petros
Kamble, Prasad G.
Pereira, Maria J.
Sundbom, Magnus
Carlsson, Per‐Ola
Eriksson, Jan W.
Espes, Daniel
author_sort Katsogiannos, Petros
collection PubMed
description OBJECTIVE: This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux‐en‐Y gastric bypass (RYGB) with healthy controls. METHODS: A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m(2) were compared with 25 healthy controls without obesity. Cytokines, adipokines, and peptides of relevance for inflammation and metabolism were analyzed in plasma. RESULTS: Significant decreases in weight and glycated hemoglobin A(1c) were observed. At baseline, interleukin‐6 (IL‐6), IFN‐β, IL‐18, leptin, and hepatocyte growth factor were higher in all patients with obesity compared with healthy controls. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, and visfatin were also increased, whereas bone morphogenic protein‐4 was decreased. Following RYGB, IL‐6 and hepatocyte growth factor were still increased in both groups compared with controls. In T2D patients, IFN‐β, IL‐27, IL‐1α, IL‐2, regenerating islet‐derived protein 3A, visfatin, and osteopontin were found to be increased. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, leptin, and visfatin remained increased. CONCLUSIONS: The altered cytokine profile of patients with obesity persisted after RYGB despite large weight loss and improved metabolic status, thus reflecting an inherent inflammatory state.
format Online
Article
Text
id pubmed-7986425
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79864252021-03-25 Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes Katsogiannos, Petros Kamble, Prasad G. Pereira, Maria J. Sundbom, Magnus Carlsson, Per‐Ola Eriksson, Jan W. Espes, Daniel Obesity (Silver Spring) Original Articles OBJECTIVE: This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux‐en‐Y gastric bypass (RYGB) with healthy controls. METHODS: A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m(2) were compared with 25 healthy controls without obesity. Cytokines, adipokines, and peptides of relevance for inflammation and metabolism were analyzed in plasma. RESULTS: Significant decreases in weight and glycated hemoglobin A(1c) were observed. At baseline, interleukin‐6 (IL‐6), IFN‐β, IL‐18, leptin, and hepatocyte growth factor were higher in all patients with obesity compared with healthy controls. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, and visfatin were also increased, whereas bone morphogenic protein‐4 was decreased. Following RYGB, IL‐6 and hepatocyte growth factor were still increased in both groups compared with controls. In T2D patients, IFN‐β, IL‐27, IL‐1α, IL‐2, regenerating islet‐derived protein 3A, visfatin, and osteopontin were found to be increased. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, leptin, and visfatin remained increased. CONCLUSIONS: The altered cytokine profile of patients with obesity persisted after RYGB despite large weight loss and improved metabolic status, thus reflecting an inherent inflammatory state. John Wiley and Sons Inc. 2021-02-23 2021-03 /pmc/articles/PMC7986425/ /pubmed/33624436 http://dx.doi.org/10.1002/oby.23093 Text en © 2021 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society (TOS) This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Katsogiannos, Petros
Kamble, Prasad G.
Pereira, Maria J.
Sundbom, Magnus
Carlsson, Per‐Ola
Eriksson, Jan W.
Espes, Daniel
Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes
title Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes
title_full Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes
title_fullStr Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes
title_full_unstemmed Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes
title_short Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes
title_sort changes in circulating cytokines and adipokines after rygb in patients with and without type 2 diabetes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986425/
https://www.ncbi.nlm.nih.gov/pubmed/33624436
http://dx.doi.org/10.1002/oby.23093
work_keys_str_mv AT katsogiannospetros changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes
AT kambleprasadg changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes
AT pereiramariaj changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes
AT sundbommagnus changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes
AT carlssonperola changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes
AT erikssonjanw changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes
AT espesdaniel changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes